Contribution
What I am about to say relates to the right hon. Member’s intervention. It is not unusual in medicine for children to participate in clinical trials, provided that there are robust safeguards, clear parental consent and proper oversight. But can a distressed teenager and a family desperate to help truly grasp these long-term implications? The legal experts I consulted spoke about the delicate ethics at play. Medical research always involves balancing competing risks: the risks of harm from an intervention versus the risks of harm from withholding it.
Puberty blocker trials pose unusual challenges as they cannot include placebos, so the design requires special scrutiny to ensure that informed consent is meaningful. There is still work to do to ensure that children and parents fully understand what entering a study means. On the other hand, opponents of the petition—those who support the new trial—say that the only way to reach clear conclusions about safety and efficacy is through rigorous, carefully monitored research. We do not yet know about the potential harms of puberty blockers for treating gender dysphoria, but we do know that the effects of cross-sex hormones can be irreversible.
Following the Cass review, NHS England proposed a very different approach from the old Tavistock model, focusing on smaller numbers and much stricter controls. The new design would have national oversight, tight eligibility criteria and a multidisciplinary team around each young person, and only about 5% of participants might receive puberty blockers compared with around 27% who were prescribed them while at Tavistock.
Also important is that cancelling the NHS trial would not prevent young people from accessing puberty blockers. In some gender clinics, clinicians report that between 10% and 20% of clients are obtaining them privately or online, outside regulated healthcare systems. Those unmonitored routes carry greater risks because dosages, purity and outcomes are not tracked or supported. Proponents of the trial point out that without direct research we remain in a state of uncertainty, which carries its own risks. If puberty blockers help some young people to avoid serious distress, we need to understand that better.
If the evidence ultimately shows that the risks outweigh the benefits, that too must be established through high-quality data. Without such evidence, none of us—doctors, parents or policymakers—can make sound judgments. Of course, participation in any trial is voluntary. Families will continue to have the right to decline. The aim of the study is not to push young people towards any one outcome, but to understand what support is appropriate for different individuals.
I want to end my speech by returning to the people at the heart of this issue. I have spoken to individuals who feel deeply harmed by medical intervention, such as Keira Bell, whose story has been widely discussed. Her experience matters, as do the experiences of all those who regret the care they have received. I have also had the pleasure to speak with Maxine Heron, whose experience with puberty blockers was profoundly positive. Having the option to pause puberty spared her immense distress, and she has experienced no negative health outcomes. For her, being forced to undergo male puberty would have been the greater trauma. She is one of many who report that their lives have been significantly improved by timely support.
We must hold both kinds of stories with equal seriousness. Regret exists, but so does gratitude. The aim of research is not to erase one side of the story, but to understand why experiences differ, and crucially, how best to help every child who is struggling. Without doubt, this is one of the most challenging questions before us: how to protect young people, respect autonomy and uphold scientific integrity. I, for one, do not pretend that it is easy.
I hope today’s debate will help to address some of the challenges, and reassure those who have signed the petition that their concerns are being taken seriously. I can see with my own eyes that many colleagues wish to contribute. I will therefore draw my remarks to a close. I look forward to the contributions to this debate, especially the reply from the Government, which I believe will be instructive.